Free Trial

Atea Pharmaceuticals (AVIR) Competitors

-0.11 (-2.99%)
(As of 07/19/2024 ET)


Should you be buying Atea Pharmaceuticals stock or one of its competitors? The main competitors of Atea Pharmaceuticals include Inovio Pharmaceuticals (INO), Gyre Therapeutics (GYRE), ARS Pharmaceuticals (SPRY), Tango Therapeutics (TNGX), Innoviva (INVA), Tyra Biosciences (TYRA), Collegium Pharmaceutical (COLL), Ironwood Pharmaceuticals (IRWD), Pacira BioSciences (PCRX), and Centessa Pharmaceuticals (CNTA). These companies are all part of the "medical" sector.

Atea Pharmaceuticals vs.

Inovio Pharmaceuticals (NASDAQ:INO) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, community ranking, risk, analyst recommendations and valuation.

Inovio Pharmaceuticals presently has a consensus target price of $56.75, indicating a potential upside of 463.56%. Given Atea Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Inovio Pharmaceuticals is more favorable than Atea Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inovio Pharmaceuticals
0 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
Atea Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)

26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 2.5% of Inovio Pharmaceuticals shares are owned by company insiders. Comparatively, 17.8% of Atea Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Atea Pharmaceuticals has a net margin of 0.00% compared to Atea Pharmaceuticals' net margin of -16,238.91%. Inovio Pharmaceuticals' return on equity of -29.18% beat Atea Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Inovio Pharmaceuticals-16,238.91% -88.13% -63.03%
Atea Pharmaceuticals N/A -29.18%-27.48%

In the previous week, Inovio Pharmaceuticals had 3 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 7 mentions for Inovio Pharmaceuticals and 4 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.86 beat Inovio Pharmaceuticals' score of 0.47 indicating that Inovio Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Inovio Pharmaceuticals
3 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Atea Pharmaceuticals
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)

Inovio Pharmaceuticals has higher earnings, but lower revenue than Atea Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inovio Pharmaceuticals$830K314.35-$135.12MN/AN/A
Atea Pharmaceuticals$351.37M0.86-$135.96M-$1.96-1.82

Inovio Pharmaceuticals received 700 more outperform votes than Atea Pharmaceuticals when rated by MarketBeat users. Likewise, 71.41% of users gave Inovio Pharmaceuticals an outperform vote while only 47.22% of users gave Atea Pharmaceuticals an outperform vote.

Inovio PharmaceuticalsOutperform Votes
Underperform Votes
Atea PharmaceuticalsOutperform Votes
Underperform Votes

Inovio Pharmaceuticals has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500. Comparatively, Atea Pharmaceuticals has a beta of 0.18, suggesting that its stock price is 82% less volatile than the S&P 500.


Inovio Pharmaceuticals beats Atea Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AVIR vs. The Competition

MetricAtea PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$300.67M$7.05B$5.23B$8.40B
Dividend YieldN/A2.67%2.81%3.93%
P/E Ratio-1.8216.43154.1017.46
Price / Sales0.86328.072,177.7987.03
Price / CashN/A32.7536.0434.86
Price / Book0.545.754.884.45
Net Income-$135.96M$147.21M$111.10M$216.15M
7 Day Performance4.08%-2.42%-0.73%-0.15%
1 Month Performance2.29%6.08%6.87%5.24%
1 Year Performance-2.72%-4.77%3.56%-0.23%

Atea Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
Inovio Pharmaceuticals
3.3736 of 5 stars
3.37 / 5 stars
-87.1%$293.05M$830,000.000.00122Short Interest ↑
Gyre Therapeutics
0.7777 of 5 stars
0.78 / 5 stars
N/AN/A$1.15B$113.45M0.00593Short Interest ↓
Positive News
ARS Pharmaceuticals
2.3678 of 5 stars
2.37 / 5 stars
+48.2%$1.10B$30,000.00-22.4224Insider Selling
Tango Therapeutics
2.9273 of 5 stars
2.93 / 5 stars
+186.8%$1.07B$36.53M-8.87140Analyst Forecast
Insider Selling
1.3719 of 5 stars
1.37 / 5 stars
N/A+35.5%$1.04B$310.46M7.59112Short Interest ↓
Tyra Biosciences
0.5582 of 5 stars
0.56 / 5 stars
Collegium Pharmaceutical
3.7147 of 5 stars
3.71 / 5 stars
+47.7%$1.04B$566.77M13.24210Positive News
Ironwood Pharmaceuticals
4.532 of 5 stars
4.53 / 5 stars
-36.4%$1.01B$442.73M-0.95267Analyst Upgrade
Positive News
Pacira BioSciences
4.6286 of 5 stars
4.63 / 5 stars
Centessa Pharmaceuticals
1.1044 of 5 stars
1.10 / 5 stars
+23.9%$990.75M$6.85M-6.72200Analyst Forecast
Short Interest ↑
News Coverage

Related Companies and Tools

This page (NASDAQ:AVIR) was last updated on 7/19/2024 by Staff

From Our Partners